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Abstract 
 
 
Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present 
from birth that markedly elevates plasma low-density lipoprotein (LDL) 
cholesterol and causes premature coronary heart disease. There are at least 
20 million people with FH worldwide, but the majority remains undetected and 
current treatment is often suboptimal. 
To address this major gap in coronary prevention we present, from an 
international perspective, consensus-based guidance on the care of FH. The 
guidance was generated from seminars and workshops held at an 
international symposium. The recommendations focus on the detection, 
diagnosis, assessment and management of FH in adults and children, and set 
guidelines for clinical purposes. They also refer to best practice for cascade 
screening and risk notifying and testing families for FH, including use of 
genetic testing. Guidance on treatment is based on risk stratification, 
management of non-cholesterol risk factors and safe and effective use of LDL 
lowering therapies. Recommendations are given on lipoprotein apheresis. The 
use of emerging therapies for FH is also foreshadowed.  
This international guidance acknowledges evidence gaps, but aims to make 
the best use of contemporary practice and technology to achieve the best 
outcomes for the care of FH. It should accordingly be employed to inform 
clinical judgment and be adjusted for country-specific and local healthcare 
needs and resources. 
 
Key Words: familial hypercholesterolaemia, international guidance, adults, 
children, screening, diagnosis, assessment, treatment, models of care.
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Endorsement 
 
The recommendations contained in this document have been fully endorsed 
by The National Lipid Association, 6816 Southpoint Parkway (Suite 1000), 
Jacksonville, FL3316, US.  
 
 
Abbreviations and Conversion Factors 
  
Abbreviations:  
ApoB, apolipoprotein B-100; CAC, coronary artery calcification; CHD, 
coronary heart disease; CK, creatine kinase; CIMT, carotid intima-medial 
thickness; CT, computerized tomography; CVD, cardiovascular disease; 
DLCNC, Dutch Lipid Clinic Network Criteria; DLCNS, Dutch Lipid Clinic 
Network Score; DRG, Diagnosis-Related Groups; FDA, Food and Drug 
Administration; FH, familial hypercholesterolaemia: GP, general practitioner; 
HDL, high-density lipoprotein; ICD, International Classification of Diseases; 
LA, lipoprotein apheresis; LDL, low-density lipoprotein; LDLR, low-density 
lipoprotein receptor; Lp(a), Lipoprotein (a); Mabs, monoclonal antibodies; 
MEDPED, Make Early Diagnosis to Prevent Early Death; MHT, menopausal 
hormone therapy; MPLA, Multiplex Ligation Probe Amplification; MTP, 
microsomal triglyceride transfer protein; PCSK9, proprotein convertase 
subtilisin-like kexin Type 9; REMS, Risk Evaluation Mitigation Strategy; VLDL, 
very low-density lipoprotein. 
 
Conversion Factors:  
mg/dL cholesterol = mmol/L x 38.7; mg/dL triglyceride = mmol/L x 88.6; mg/dL 
lipoprotein(a) = 0.0357µmol/L.
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Levels of Evidence and Grades of Recommendation 
 
Levels of Evidence: 
1= systematic review/meta-analysis/at least one randomised control trial/good 
quality diagnostic tests.  
2 = good quality clinical or observational studies. 
3 = expert opinion or clinical experience/argument from first principles. 
 
(The evidence for therapeutic interventions was considered principally in 
respect of effects on plasma LDL-cholesterol concentrations, but where 
available was also based on data on subclinical atherosclerosis or 
cardiovascular outcomes.) 
 
Grades of Recommendation: 
A = can be trusted to guide practice. 
B = can be trusted to guide practice in most situations. 
C = can be used to guide practice, but care should be taken in application.  
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Summary of Recommendations 
  
1. Detection of Index cases: Screening and Phenotypic Diagnosis 
 
1.1 Targeted, opportunistic and universal screening strategies should be employed to 
detect index cases [2B]. 
1.2 Index cases should be sought by targeted screening of adults with premature 
cardiovascular disease (CVD), primarily coronary heart disease (CHD) and a 
personal and/or family history of hypercholesterolaemia. [1A ] 
1.3 Opportunistic screening of adults and children in primary care, based on age- and 
gender-specific plasma LDL-cholesterol levels, should be routinely adopted. [2B] 
1.4 Universal screening based on age- and gender- specific plasma LDL-cholesterol 
levels should be considered prior to age 20 years and ideally before puberty. [2C] 
1.5 In adults, country-specific clinical tools, such as the Dutch Lipid Clinic Network, 
Simon Broome, MED-PED or Japanese FH criteria, may be used to make a 
phenotypic diagnosis. [1A] 
1.6 The effect of acute illness and concurrent use of statins in lowering plasma LDL-
cholesterol must be considered: testing for FH should not be carried out during acute 
illness; LDL-cholesterol level should be appropriately adjusted in people on statins, 
particularly if a reliable pre-treatment value is not available [2A] 
1.7  All patients with suspected FH should be referred to a clinic specialising in 
lipidology and/or metabolic disorders for further assessment, if such a service is 
available. [3A] 
 
2. Diagnosis and Assessment of Adults 
 
2.1 Secondary causes of hypercholesterolaemia should first be excluded. [1A] 
2.2 The most reliable diagnosis of FH can be made using both phenotypic (see 1.5 
above and 4.8 below) criteria and genetic testing, but when genetic testing is not 
available the diagnosis can be made phenotypically. [1A] 
2.3 DNA testing increases the accuracy of detecting FH and, if resources permit, 
should be considered to confirm the diagnosis, especially if cascade screening is 
planned; a fully accredited laboratory should be used. [1A] 
2.4  Although FH is a life-time coronary risk equivalent, patients should be assessed 
for additional major cardiovascular risk factors, including lipoprotein(a) [Lp(a)], the 
level of hypercholesterolaemia at diagnosis and the prematurity of the family 
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(especially first-degree relatives) or personal history of CVD. Framingham or other 
cardiovascular risk equations should not be used. [2A]  
2.5 The presence of additional cardiovascular risk factors should guide the intensity 
of medical management. [2A]  
2.6 Cardiovascular imaging (eg. cardiac computed tomography and carotid 
ultrasonography) may be useful for assessing asymptomatic patients, but its value is 
not fully established. [2C]  
  
3.  Diagnosis and Assessment of Children and Adolescents 
 
3.1 Secondary causes of hypercholesterolaemia should first be excluded. [1A] 
3.2 With the exceptions noted in 3.3, children should be genetically tested for FH only 
after a pathogenic variant (mutation) has been identified in a parent or first degree 
relative. [1A] 
3.3 Children may initially be genetically tested for FH when parents or first degree 
relatives are unknown or deceased, or as an accepted screening practice in certain 
countries, such as the Netherlands [3B]  
3.4 Age-, gender- and country -specific plasma LDL-cholesterol concentration 
thresholds should be used to make the phenotypic diagnosis; because of biological 
variation, two fasting LDL-cholesterol values are recommended.[1B] 
3.5 A plasma LDL-cholesterol of 5.0 mmol/L or above indicates high probability of FH 
in the absence of a positive parental history of hypercholesterolaemia or premature 
CHD; an LDL-cholesterol of 4.0 mmol/L or above indicates high probability of FH in 
the presence of a positive parental history of hypercholesterolaemia or premature 
CHD [1B] 
3.6 Patients should be risk stratified according to age, presence of other 
cardiovascular risk factors, family history of early onset CVD (especially in first-
degree relatives) and the level of LDL-cholesterol at diagnosis. [2A]  
3.7 The presence of additional cardiovascular risk factors, and hence risk 
stratification, should guide the intensity of medical management. [3A] 
3.8  Carotid ultrasonography may be employed to assess risk, but its value is not fully 
established; it should only be carried out in centres with specific expertise. [2C]  
3.9 Cardiac CT should not be used routinely to assess patients with heterozygous 
FH. [3A] 
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4.  Cascade Screening: Testing and Risk Notification of Families 
 
4.1 Notification of relatives at risk of FH should generally not be carried out without 
the consent of the index case. [3A]  
4.2 Relatives should only be directly notified of their risk without consent of the index 
case if there is specific legislative provision for breach of confidentiality in the 
relevant jurisdiction. [3C] 
4.3 A proactive approach that respects the principles of privacy, justice and 
autonomy is required. [3A] 
4.4 Pre-testing counselling should be offered to at risk family members of an index 
case prior to any form of testing. [1A] 
4.5 Systematic cascade screening should ideally be co-ordinated by a dedicated 
centre and should not be carried out in primary care without central co-ordination, 
particularly if employing DNA testing. [1B] 
4.6 Cascade screening of families should be carried out using both a phenotypic and 
genotypic strategy, but if DNA testing is not available a phenotypic strategy alone 
should be used [1A] 
4.7 Cascade screening should initially be carried out as a priority in first-degree 
relatives and then extended to second- and third-degree relatives. [1A]  
4.8 In the absence of genetic testing, the diagnosis of FH should be made in close 
relatives using age- , gender- and country- specific plasma LDL-cholesterol levels. 
Diagnostic clinical tools for index cases, such as the Dutch Lipid Clinic Network and 
Simon Broome criteria, should not be employed to make the diagnosis of FH in 
relatives [1A ]  
4.9 DNA testing makes cascade screening more cost-effective and should be 
employed to screen family members after the mutation is identified in the index case. 
[1A] 
4.10 Children with xanthomata or other physical findings of homozygous FH, or at 
risk of homozygous FH should be screened as early as possible and definitely by 2 
years of age. [2A] 
4.11 Children with suspected heterozygous FH should be screened between the 
ages of 5 and 10 years; age at screening should be similar in boys and girls. [ 2B] 
 
5. Genetic Testing 
 
5.1 Genetic testing for FH should ideally be offered to all ‘index cases’ who have a 
phenotypic diagnosis of FH. [3A]  
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5.2 When the phenotypic diagnosis of FH is unlikely (e.g. by Dutch Lipid Clinic 
Network Criteria), genetic testing of the ‘index case’ need not be carried out. [1C] 
5.3 Genetic testing for FH must be carried out in an accredited laboratory using 
standardised methods that target specific mutations and/or by exon-by-exon 
sequencing. [1A] 
5.4 If genetic testing detects a variant, its significance as a pathogenic mutation, a 
previously reported variant of uncertain significance, a novel variant of uncertain 
significance or a benign (normal) variant needs to be assessed and recorded. [1A] 
5.5 If genetic testing does not detect a variant, FH due to undetected mutations or 
mutations in untested genes cannot be excluded, particularly if the clinical phenotype 
is strongly suggestive of FH. [1A] 
 
6. Management of Adults 
 
6.1 All adult patients with FH must receive advice on lifestyle modifications and 
advice to correct all non-cholesterol risk factors should be provided according to 
expert recommendations. [2A] 
6.2 Therapy should ideally aim for at least a 50% reduction in plasma LDL-
cholesterol, followed by an LDL-cholesterol < 2.5 mmol/L (absence of CHD or other 
major risk factors) and < 1.8 mmol/L (presence of CHD or other major risk factors). 
[2C]  
6.3 Achieving these targets will require a fat-modified, heart-healthy diet and statin 
therapy with or without ezetimibe. [1A] 
6.4 Drug combinations including bile acid sequestrants, niacin, probucol or fibrates, 
may be required with more intensive strategies to further reduce LDL-cholesterol. 
[1B] 
6.5 Plasma levels of hepatic aminotransferases, creatine kinase, glucose and 
creatinine should be measured before starting drug therapy. All patients on statins 
should have hepatic aminotransferases monitored; creatine kinase should be 
measured when musculoskeletal symptoms are reported; glucose should be 
monitored when there are risk factors for diabetes. [2A] 
6.6 All women of child-bearing age should receive pre-pregnancy counselling, with 
appropriate advice on contraception, before starting a statin and this should be 
reinforced at annual review. [2A] 
6.7 Statins and other systemically absorbed lipid regulating drugs should be 
discontinued 3 months before planned conception, as well as during pregnancy and 
breast feeding. [2A] 
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6.8 Although carotid ultrasonography has been used in clinical trials, its role in 
monitoring therapy as part of the clinical care for FH has not been established and it 
should therefore not be used at present for this purpose. [3C] 
6.9 Lomitapide and Mipomersen should be considered as adjunctive treatments to 
diet and cholesterol lowering drugs in adults with homozygous FH to further reduce 
plasma LDL-cholesterol, particularly if lipoprotein apheresis is not available. [1C] 
6.10 Well controlled and low complexity patients should be followed-up in primary 
care, whereas higher complexity patients will need regular review by a specialist, with 
the option of shared care. Review intervals should vary according to clinical context. 
Opportunities should be created for integrating the primary and specialist care of FH. 
[3B] 
 
7. Management of Children and Adolescents 
 
7.1 Patients must receive advice on lifestyle modifications and on correcting non-
cholesterol risk factors; primordial prevention (counselling to inhibit the development 
of risk factors) is particularly important. [2A]  
7.2 To lower elevated plasma LDL-cholesterol in this age group generally requires a 
fat-modified, heart-healthy diet and a statin, with the possible addition of ezetimibe or 
a bile acid sequestrant. [1A] 
7.3 All patients should be treated with diet, with statins considered at age 8 to 10 
years and ideally started before age of 18 years; plasma LDL-cholesterol targets in 
this age group need not be as intense as for adults [2B] 
7.4 Boys and girls should generally be treated at similar ages, although with a 
particularly adverse family history of CHD and other major risk factors, boys with 
heterozygous FH could be considered for earlier treatment with statins. [2B] 
7.5 Children, between the ages of 8 and 10 years, with proven FH on a suitable diet 
and LDL-cholesterol > 4.0 mmol/L on two occasions should be started on low-dose 
statin monotherapy, aiming for an LDL-cholesterol < 4.0 mmol/L.[3C] 
7.6 After the age of 10 years, children with proven FH on a suitable diet and LDL-
cholesterol > 3.5 mmol/L on two occasions should be started on statin monotherapy, 
aiming for an LDL-cholesterol < 3.5 mmol/L, with the addition of ezetimibe or a bile 
acid sequestrant if required. [3C] 
7.7 The preferred statins for initiating therapy are those that are licensed for clinical 
use in this age group in specific countries; other statins may be prescribed according 
to clinical indications, higher doses of potent statins being required in homozygotes. 
[1C] 
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7.8 Although statins can be safely used in children, weight, growth, physical and 
sexual development, and well-being should be monitored in this age group. [1A]  
7.9 Plasma levels of hepatic aminotransferases, creatine kinase, glucose and 
creatinine should be measured before starting drug therapy. All patients on statins 
should have hepatic aminotransferases monitored; creatine kinase should be 
measured and compared to pre-treatment levels when musculoskeletal symptoms 
are reported; glucose should be monitored if there are risk factors for diabetes. [2A] 
7.10 All adolescent girls should receive pre-pregnancy counselling, with appropriate 
advice on contraception, before starting a statin and this should be reinforced at 
annual review. [3A]. 
7.11 Although carotid ultrasonography has been used in clinical trials, its role in 
monitoring therapy in patients with heterozygous FH has not been established and it 
should therefore not be used for this purpose. [3C] 
7.12 Well controlled and lower complexity patients should be followed up in primary 
care, whereas higher complexity patients will need regular review by a paediatrician. 
Opportunities should be created for integrated care between GPs and paediatricians. 
Family based and transitional care clinics should be considered by adult and 
paediatric services. [3B] 
7.13 Children with homozygous FH should be referred on diagnosis to a specialist 
centre and drug and/or apheresis treatment commenced as soon as possible. [2A]  
7.14 In children with homozygous FH and rapidly progressive atherosclerosis, 
Lomitapide and Mipomersen, although not yet tested in children, should be 
considered, employing special access or compassionate use schemes, as adjunctive 
treatments to diet and conventional drugs to further reduce plasma LDL-cholesterol, 
particularly if apheresis is not available or declined by the patient/family. [3C] 
 
8. Lipoprotein apheresis and related treatments 
 
8.1 Lipoprotein apheresis (LA) should be considered in all patients with homozygous 
or compound heterozygous FH (i.e. homozygous FH phenotype) and carried out in a 
dedicated centre with the relevant expertise. [1A]  
8.2 LA should be considered in patients with heterozygous FH with CHD who cannot 
achieve LDL-cholesterol targets despite maximal drug therapy or because they 
cannot tolerate statins. [2A] 
8.3 LA should be considered in children with homozygous FH by the age of 5 and no 
later than 8 years. [2A] 
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8.4 Diet and drug therapy to lower LDL-cholesterol should be continued during 
treatment with LA [2A]. 
8.5 The efficacy, tolerability and safety of LA must be regularly reviewed. [3A] 
8.6 The effect of LA on progression of atherosclerosis should be monitored according 
to clinical indications in FH patients with echocardiography (aortic valve and root), 
carotid ultrasonography and exercise stress testing. [3B]  
8.7 Lomitapide should be considered as an adjunctive to standard diet and drug 
therapy to further lower plasma LDL-cholesterol in adults with homozygous FH on 
LA. [1C] 
8.8 Lomitapide should be considered, via a special access scheme, as an adjunctive 
treatment to further lower plasma LDL-cholesterol in children and adolescents with 
homozygous FH on LA with rapidly progressive atherosclerosis. [3C] 
8.9 Mipomersen should be considered as an adjunctive to standard diet and drug 
therapy to further lower plasma LDL-cholesterol in adults, children and adolescents 
with homozygous FH on LA who cannot tolerate lomitapide. [3C] 
8.10 If available, orthotopic liver transplantation should be considered for younger 
patients with homozygous FH who have rapid progression of atherosclerosis or aortic 
stenosis, cannot tolerate LA or when plasma LDL-cholesterol cannot be adequately 
lowered with LA, diet and drug treatment. [3B] 
 
9. Organization and Development of Care 
 
9.1 Care pathways for FH should be developed for country-specific and local needs. 
[3A] 
9.2 Specialist services should be multidisciplinary based and integrated with primary 
care. [3B]  
9.3 Specialist care of FH should ideally be supported by cardiology, paediatric, 
genetic, imaging, transfusion medicine, nursing, dietetic, psychology, pharmacy and 
pathology laboratory services. [3A] 
9.4 Cascade screening should ideally be centrally co-ordinated by a dedicated 
centre. [1A] 
9.5 Low complexity patients should be managed in primary care, with the option of 
annual specialist review. [3A] 
9.6 Higher complexity patients should be managed principally in specialist centres. 
[3A] 
9.7 Medical, nursing and allied health staff managing patients with FH should be 
accredited in cardiovascular prevention. [3A] 
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9.8 Services should establish partnerships with academic and professional 
organizations to enhance teaching, training and research. [3A] 
9.9 A registry of patients and families should be established for clinical, research and 
audit purposes. [3A] 
9.10 A support group of patients and families should be established as a major 
priority for enhancing public, government and health care provider awareness, as 
well as the total quality of care of FH. [3A] 
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Introduction 
 
 
Familial hypercholesterolaemia (FH) is the most common dominantly inherited 
disorder in man [1]. FH is most frequently due to dominant, loss of function 
mutations in genes affecting the low-density lipoprotein (LDL) receptor that 
clears LDL particles from plasma [2], and therefore LDL-cholesterol levels is 
markedly elevated from birth. FH accelerates atherosclerotic cardiovascular 
disease (CVD), especially coronary heart disease (CHD), with clinical 
manifestations often occurring after one to four decades of life [3, 4]. 
Screening allows early detection of individuals [5-9], thereby allowing use of 
preventive interventions including lifestyle measures, cholesterol-lowering 
medications and management of other CVD risk factors [6-16]. There are 
probably more than 15 million people with FH worldwide, but less than 10% 
have been detected and only 5% adequately treated [3, 4, 17, 18]. 
 
To address this major gap in coronary prevention, the International FH 
Foundation facilitated a series of discussions with experts to develop 
harmonized guidance for the care of FH. Formal presentations and informal 
discussions took place at the XVI International Symposium on Atherosclerosis 
(Sydney, 2012) in workshops that addressed evidence for treatment, 
screening and DNA testing, paediatric management, novel therapies, health 
economics, regional diversity in management, and models of care. Workshop 
moderators identified and collated consensus based on published research, 
clinical experience, common themes, expert opinion, and other international 
guidelines on FH [6-9, 19-22]. To supplement this process a brief 
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questionnaire on potentially contentious issues in FH (screening options, DNA 
testing, risk stratification, testing and treatment of children, use of imaging, 
and therapeutic targets) was then completed by a selected group of 
international experts, with the majority view employed to inform further 
consensus. This international guidance presents a standard of care for FH 
patients within in a framework that can be adjusted for country-specific, 
regional and local requirements, and within which future evidence and 
consensus may be developed [23]. 
 
Detection of Index Cases: Screening for FH 
 
 
A systematic strategy for detecting index cases (i.e. first individuals diagnosed 
in families) of FH is essential [6-9]. The index case is the trigger for cascade 
screening, whereby new cases can be efficiently discovered [3, 8, 9]. Both 
screening methods need to be well integrated in models of care [8]. Universal 
screening prior to age 20 years and ideally before puberty, based on age- and 
gender-specific plasma LDL-cholesterol levels, should also be considered if 
feasible [9, 21]. However, experience concerning its use and implementation 
is very limited. From a population perspective, universal and cascade 
screening methods for FH should be closely integrated [24]. The success of 
all detection strategies will depend on adequately addressing several barriers, 
including population awareness of FH and family, physician and societal 
concerns of the value of screening for FH. 
 
Potential index cases of FH should be sought amongst patients aged less 
than 60 years with CVD presenting to coronary care, stroke, cardiothoracic 
17 
 
and vascular units [8, 25], as well as amongst similar patients attending 
cardiac rehabilitation programs. The greatest yield will be from screening 
younger adult patients with CHD [25, 26]. A coronary event in a family 
member can increase the perception of risk and the willingness of relatives to 
be subsequently tested for FH. Screening in primary care should employ an 
initial non-fasting lipid profile [8], which should be undertaken 
opportunistically, based on family history of hypercholesterolaemia and 
premature CVD (age < 60 years) [27, 28]. FH screening should also be 
offered to all patients with tendon xanthomata and premature arcus cornealis 
[6-9, 22]. All forms of opportunistic screening should account for the effect of 
any acute illness in lowering plasma total and LDL-cholesterol [28, 29], in 
which case lipid testing should be delayed or repeated at least 8 weeks after 
recovery. There is a role for community laboratories alerting primary care 
physicians about FH on the basis of a high plasma LDL-cholesterol ( eg > 5 
mmol/L) or high total cholesterol (e.g. > 7 mmol/L) [30]. When feasible, all 
patients with suspected FH should be referred to a specialist with expertise in 
FH for confirmation of the diagnosis [26, 28, 31]. All patients with homozygous 
FH (untreated LDL-cholesterol > 13 mmol/L; treated LDL-cholesterol > 7.5 
mmol/L) [32] must be referred to the nearest specialist centre for management 
[8, 31, 33]. 
 
Diagnosis and Assessment of Adults 
 
 
There are a number of criteria for diagnosing FH phenotypically in adults, but 
none are internationally agreed [6-9, 22]. The Dutch Lipid Clinic Network 
Criteria (DLCNC) are used to calculate a numerical score predicting the 
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probability of the diagnosis of FH [34]. These criteria are increasingly 
accepted as simple and comprehensive [8, 13, 34]; the numerical score is not 
highly dependent on the plasma level of LDL-cholesterol and can be more 
sensitive in detecting index cases, with a score > 5 making the diagnosis 
highly probable. The Simon Broome system is comparable to the DLCNC in 
predicting an FH mutation, but does not employ arcus cornealis and may also 
overlook patients with true FH who are not overtly hypercholesterolaemic. The 
MEDPED System, which relies on plasma total and LDL-cholesterol and 
strictly requires that cholesterol measurements be first known in other family 
members [35], may also be less specific in predicting mutations than other 
methods. The Japanese criteria, which are comparable to the Simon Broome 
system, employ a population-specific LDL-cholesterol > 4.7mmol/L and allow 
for a radiographic diagnosis of Achilles tendon xanthomata [22]. Further 
international research is required to establish simple and harmonised criteria 
for the clinical diagnosis of FH. 
 
The diagnosis of FH should be based on at least two fasting measures of 
plasma LDL-cholesterol [8, 10, 13]. Obtaining the family history of CHD and 
hypercholesterolaemia is important to enhance the phenotypic diagnosis [6, 
26, 34-36], but this information is often neglected or may not be available in 
practice [25, 37]. The presence of tendon xanthomata in early life with marked 
elevation in plasma LDL-cholesterol establishes the diagnosis of severe FH 
[32], but sitosterolaemia should also be excluded with plasma phytosterol and 
DNA testing [38]; in adults, tendon xanthomata with normal plasma 
cholesterol may be seen in sitosterolaemia and cerebrotendinous 
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xanthomatosis. Secondary causes of hypercholesterolaemia (e.g. 
hypothyroidism, proteinuria, medications) must be excluded [8, 13, 22], but 
the clinical stigmata of FH do not occur in these conditions. LDL-cholesterol is 
underestimated by the Friedewald equation if the plasma triglyceride level is > 
4.5 mmol/L [28], when a direct LDL-cholesterol assay should be employed. 
The levels of apoB and non-HDL-cholesterol (i.e. total cholesterol minus HDL-
cholesterol) for diagnosing FH have not been defined. FH must be 
distinguished from familial combined hyperlipidaemia [22, 39], a multigenic 
disorder with a variable lipid phenotype that co-expresses with insulin 
resistance and does not exhibit tendon xanthomata. Significant 
hypertriglyceridaemia makes the diagnosis of FH less likely, but may rarely be 
seen with co-existing genetic defects in lipoprotein metabolism [40, 41]. For 
patients on cholesterol lowering medication, pre-treatment LDL-cholesterol 
values must be obtained or interpolated from the drug type and regimen used 
[42]. 
 
All patients diagnosed with FH should be investigated for other CVD risk 
factors [8, 22, 43, 44] and the presence of symptomatic or subclinical 
atherosclerosis [7, 8, 45]. Assessment must take account of the psychological, 
intellectual, social and ethnic status of the patient [46, 47]. Detailed and 
culturally appropriate exploration of the individual’s family history of CVD, 
particularly among first-degree relatives, is essential. Risk of CVD amongst 
patients with FH can vary widely [43, 44]. This may relate to the pre-treatment 
plasma level of cholesterol, genetic causes affecting lipid metabolism or 
arterial biology, and the presence of other major risk factors, in particular 
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smoking, obesity, low HDL-cholesterol, hypertension and diabetes [43, 44]. 
Mutations that very markedly elevate plasma LDL-cholesterol [48] and 
independently increase plasma Lp(a) concentrations also enhance the risk of 
CVD in FH [49]. Elevated Lp(a) may also contribute to the development of 
aortic stenosis [50]. Framingham Risk Scores, or scores derived from other 
cardiovascular risk engines, are not reliable to guide management in FH and 
should not be used [8, 10, 11], particularly in younger patients, in whom a 
measure of long-term risk based on imaging of subclinical atherosclerosis 
may be more appropriate [14, 51, 52]. An assessment of cholesterol-life 
years, or cumulative cholesterol burden, may also be useful in risk 
assessment [53], but its value in managing individual patients requires 
evaluation. 
FH is associated with early onset and increased burden of subclinical 
atherosclerosis [52, 53]. Certain measures of subclinical atherosclerosis have 
been independently associated with the onset of CHD in the general 
population [54, 55], but have been generally applied to FH in research settings 
alone and require further evaluation. Increased carotid intima-medial 
thickness (CIMT) and the presence of plaques may be assessed by carotid 
ultrasonography [52, 54, 56]. Coronary artery calcification (CAC) and luminal 
obstruction can be assessed with cardiac computed tomography/angiography 
[45, 54, 57]. In asymptomatic individuals, CAC score may be superior to CT 
coronary angiography in risk prediction [58], and more clinically useful than 
CIMT [59]. Non-invasive testing for atherosclerosis could be useful in the 
assessment and management of FH, but this is not established. Testing could 
be individualized to specific clinical situations [57, 60], being particularly useful 
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when the family history of CVD is unclear [61]. Subclinical atherosclerosis 
should be defined according to recognized criteria [54]. Reference intervals for 
common CIMT have recently been reported [62], but have not been validated 
in FH. Echocardiography for aortic stenosis may be indicated for 
heterozygous individuals with marked elevation in plasma Lp(a) concentration 
[49, 50], and as a routine investigation in homozygous FH to diagnose both 
aortic and/or supra-aortic valve disease [8, 32, 43-45, 63]. 
 
Given that CVD risk and the clinical expression is variable in FH, it is 
reasonable to employ some form of risk stratification. Subdivision into lower, 
(absence of CHD, subclinical atherosclerosis and major risk factors) and 
higher (presence of CHD, subclinical alterations or major risk factors) risk can 
guide the intensity of medical management [7, 8]. The cost-effectiveness of 
this therapeutic approach requires evaluation, however. Patients considered 
to have a homozygous FH phenotype should be classified at exceptionally 
high risk [32], and be referred to a specialist centre for consideration for 
lipoprotein apheresis [64] or trial of new therapies [8]. 
 
Diagnosis and Assessment of Children and Adolescents 
 
FH should be identified in youth, certainly before 18 years of age and younger 
if indicated and feasible [19-21, 53, 65, 66]. This is particularly important for 
those at risk for homozygous FH, where recognition at about 2 years or even 
earlier is considered optimal [19-21, 53, 65, 66]. Sitosterolaemia may 
masquerade as homozygous FH in childhood and the diagnosis should be 
considered [38]. Boys and girls with potential heterozygous FH should also be 
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screened before the age of 10 years, preferably between ages of 5 and 10 
years. However, earlier screening may be justified with a family history of 
CHD prior to age 55 years, especially in first-degree relatives [63, 67, 68], or 
at the specific request of parents wishing to embed healthy lifestyle measures 
at a very early age. Detection of FH in childhood employing three strategies 
can be considered: cascade screening, universal screening, or selective 
screening based on family history [21, 27, 66]. Different countries will utilize 
different strategies based on health care resources and recommendations by 
local expert groups. In several European countries and Australia, cascade 
screening based on genetic testing has been advocated [5, 6, 8, 19], whereas 
in the United States selective screening beginning at age 2 years and 
universal screening at age 9-11 years has been advocated [9, 20]. Universal 
screening by age 20 years, and ideally before puberty, is recommended; 
universal screening has been practised in Slovenia [21] and tested in some 
universities in Japan, but the yield and cost-effectiveness remain unclear. 
Universal screening of children, followed by child-parent testing may be a 
more effective approach to detecting FH in the population than cascade 
screening alone [24]. Importantly, none of the aforementioned paediatric 
screening strategies for FH have hitherto been validated for efficacy, risk-
benefit and cost-effectiveness [69]. 
 
 Age- and gender-specific plasma LDL-cholesterol concentration 
thresholds should be used to make an initial diagnosis of FH [67, 70]. Plasma 
LDL-cholesterol level alone has excellent discrimination between those with 
and without FH below the age of 10 years [67, 70, 71]. However, because of 
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biological variation [29, 72], the average of at least two fasting LDL-cholesterol 
levels should be used to make the diagnosis of FH [19, 20, 65]. The effects of 
acute illness in lowering LDL-cholesterol should be accounted for and tests 
repeated if necessary [29, 72]. The diagnosis of heterozygous FH is highly 
likely in children over 2 years of age if the LDL-cholesterol level is greater or 
equal to 5 mmol/L [67, 68], even in the absence of a family history of 
hyperlipidaemia and premature CHD. Heterozygous FH is also probable at 
untreated LDL-cholesterol levels between 4 and 5 mmol/L, especially in the 
setting of a positive family history [67]. Homozygous FH should be considered 
if the untreated LDL cholesterol level is > 13 mmol/L, especially if xanthomata 
are evident before age 10 years [19, 20, 32, 65, 73]. Secondary causes of 
hypercholesterolemia, including nephrotic syndrome and hypothyroidism, 
should be excluded before diagnosing FH [19, 20, 65]. 
 As for adults, a complete CVD risk assessment including determination 
of blood pressure, body mass index, tobacco use, glucose and lipoprotein(a) 
should be performed [19, 20, 65]. The presence of these additional risk 
factors, or other high risk paediatric conditions, such as diabetes mellitus, 
Kawasaki disease with giant aneurysms or chronic kidney disease, may be an 
indication for intensification of lipid lowering treatment [73]. Eliciting a positive 
family of early CVD, especially among first-degree relatives [63, 67, 68], is 
important for planning therapy. 
 
 Subclinical atherosclerosis imaging, using CIMT and assessment of 
CAC by CT scanning [52, 74], has been used in research settings to 
determine the presence of early atherosclerosis in children with FH. Its 
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practical value remains to be established, however. There are significant 
limitations to using subclinical atherosclerosis imaging to monitor treatment in 
clinical practice [54]. Measurement of CIMT requires special expertise [75]. 
The recently reported standardised reference intervals for common CIMT [62] 
excluded children. 
 
There are also no accepted thresholds for defining the presence and 
progression of atherosclerosis in children by CIMT. CIMT measurements are 
highly age-dependent and poorly reproducible in young children, making 
assessment of change difficult [74]. Assessment of CAC is not recommended, 
since it may be absent in early atherosclerosis due to cholesterol-rich plaques, 
does not regularly develop until mature adulthood, and repeat CT scans 
increase the exposure to radiation [54]. 
 
Cascade Screening: Risk Notification of Families 
 
 
The most cost-effective approach for detecting new cases of FH is family 
cascade screening of close relatives of a diagnosed index case using a 
phenotypic or genotypic strategy [5, 6, 8, 76, 77]. Diagnostic testing based on 
a pathogenic mutation is more accurate, however, than using the phenotype 
alone [78]. If a DNA testing service is not available, cascade screening should 
be carried out using age-, gender- and country-specific plasma LDL-
cholesterol levels alone [70]. Because of higher pre-test probability, clinical 
diagnostic tools for index cases should not be used for relatives. The drawing 
of a family pedigree can be valuable in planning the screening process [6, 8, 
33]. Cascade screening should start with first-degree relatives (i.e. parents, 
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siblings, offsprings) and then be extended to second- and third-degree 
relatives [6, 8, 33]. 
 
Risk Notification 
Risk notification underpins cascade screening [6, 8, 79]. Risk notification 
informs relatives of their risk of FH, the implications for their health, and the 
availability of clinical and/or genetic testing. Fundamental ethical precepts 
regarding autonomy, beneficence and justice must be followed.  
Contacting and Informing Families 
Cascade screening should begin by contacting first- and then second- degree 
relatives, who then become probands for risk notification of their own relatives 
[6, 8, 80]. The index case should discuss family risk notification with the 
clinician or nurse, who will construct a family pedigree and identify relatives 
who should be offered testing for FH [6, 8, 33]. Relatives may be approached 
either by the index case, the clinical service, or by both [6, 8, 79]. Dual risk 
notification may be the best option. Genetic counsellors must be involved 
when sensitive family issues are identified [6, 8, 33]. 
 
Index cases should be provided with written information which clearly explains 
the diagnostic testing process and implications, and be encouraged to give 
this to their relatives [6, 8, 33]. Information sent to relatives should be written 
in general language to avoid alarm and concern, while emphasizing the 
voluntary nature of testing [8, 79], and the health consequences of a diagnosis 
of FH being missed if a person decides not to be tested. Communications 
should also emphasise the health gains of diagnosis and treatment [6, 8, 33]. 
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In the absence of a response to the first letter, a second approach by letter or 
telephone call may be made to the family member [8]. Family members who 
consent to being assessed for FH should be offered a standard plasma lipid 
profile and a genetic test if the family mutation is known and DNA testing 
available [6, 8, 78, 80]. All individuals with potential FH should be made aware 
and understand the implications of genetic testing for certain types of 
insurance cover [8, 81]. Systematic cascade screening for FH is best co-
ordinated centrally by a dedicated service that operates closely with primary 
care and ideally with a patient organization [6, 8, 31]. Cascade screening 
should be developed for country-specific and local needs [8]. In less 
developed countries, family testing in the home environment at weekends 
may increase the yield of cascade screening, noting also the opportunity for 
testing extended family members at the invitation of the index case.  
 
Risk Notification without Consent 
If the index case does not consent to risk notification of family members it is 
important to comprehend the rationale behind this, and particularly the family 
dynamics [8, 45, 79, 82]. A decision to risk notify without the consent of the 
index case should be carefully taken, with attention to the privacy legislation in 
different countries and localities [8, 83]. FH is a potentially lethal condition and 
if there are high risk features in the family, such as a strong history of 
premature CVD, contacting of relatives without consent could be justifiable [8, 
83]. 
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Genetic Testing 
 
FH is a dominantly inherited disorder, affected individuals having a 50% 
chance of passing the causative mutation to each offspring [1-3]. The majority 
of cases of FH are due to mutations in the LDL-receptor (LDLR), 
apolipoprotein B-100 (APOB) and proprotein convertase subtilisin/kexin type 9 
(PCSK9) genes [2]. A pathogenic mutation in one of these genes is identified 
in about 70% of phenotypically definite FH and 20% of phenotypically 
probable/possible FH [78, 84-86]. New molecular techniques, such as whole 
exome sequencing, can lead to the discovery of novel mutations [87]; this may 
be particularly applicable to under-studied multiethnic populations [88]. 
Absence of a pathogenic mutation in the presence of a high LDL-cholesterol 
gene score may indicate polygenic hypercholesterolaemia, and this may be 
used to limit further search for novel FH causing mutations [89]. About 95% of 
the identified mutations are in the LDLR gene, 4 -5% in the APOB gene and < 
1% in the PCSK9 gene [2, 78]. Detection of a mutation in a family member 
allows the definite diagnosis of FH to be made [2, 5, 6, 8, 78]. However, failure 
to detect a mutation does not exclude a diagnosis of FH, particularly if the 
clinical phenotype is highly suggestive of FH [6, 8]. To optimize the use of 
resources, DNA testing may only be offered to index patients with DLCNS >5 
or meeting the Simon Broome possible criteria, especially those with a 
personal history of early onset (<60 years) CVD or imaging evidence of 
significant subclinical atherosclerosis [8, 57, 84-86]. 
 
If a pathogenic mutation is identified in an index case, genetic testing is a 
cost-effective, accurate and acceptable approach for detecting new cases [77, 
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90]. Because of ethical issues involved in genetically testing minors [8, 91], it 
is best to first genetically test a phenotypically affected parent. Children may 
initially be genetically tested when parents or first-degree relatives are 
unknown or deceased [8, 19], or with due parental consent, as an acceptable 
screening practice in certain countries, e.g. The Netherlands [67, 68]. Genetic 
testing of families for FH should be co-ordinated by a specialist service with 
appropriate education and counselling offered to all individuals [5, 6, 8, 33]. 
Genetic testing in children can be carried out without invasive venepuncture, 
using a buccal swab or saliva specimen [8]. 
 
Genetic testing for FH has a Tier 1 level of evidence that strongly supports its 
application in clinical practice [92]. Genetic testing for FH should be carried 
out in an accredited laboratory that will issue timely results to the requesting 
medical practitioner [8]. A full sequencing strategy that covers point mutations 
and insertions/deletions should be performed for the LDLR and PCSK9 
genes, and for relevant parts of exons 26 and 29 of the apoB gene [84-86, 
93]. Screening for large rearrangements with MPLA analyses should be 
carried out in people with a high probability of FH in whom no functional 
mutations are detected [94]. Accredited laboratories have processes for 
assessing identified gene mutations or variants and for classifying the variant 
as clearly pathogenic (a mutation), clearly non-pathogenic (a benign variant) 
or of uncertain significance (a variant of uncertain significance) [8]; more than 
1200 genetic variants in the LDLR have so far been described, but only 79% 
are recognised to be pathogenic [95]. The process of screening for genetic 
mutations, confirming identified genetic variants, assessing pathogenicity and 
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issuing a formal report should ideally not take longer than three months [8]. 
However, genetic mutations may not be detected in 30% of patients with a 
definite clinical diagnosis of FH [78, 84-86]. In such patients, multiple genetic 
variants that affect cholesterol metabolism interact to produce a phenocopy of 
FH [89], but genetic screening of family members will not be useful. Thus, in a 
smaller proportion of families, diagnostic testing should be carried out 
phenotypically using LDL-cholesterol. Specific reference ranges for patients 
with high likelihood, low likelihood and diagnosis uncertain will have to be 
derived from populations with and without FH in each country [70]. Clinical 
management of patients should evidently be based on the plasma lipid 
phenotype and overall CVD risk status, and not on the genetic test result [6, 8, 
9, 60]. 
 
Management of Adults 
 
FH is associated with a moderately severe to very severe increase in the 
lifelong exposure to the atherogenic effects of LDL-cholesterol [53, 66]. It 
warrants aggressive, life-long management from a young age [19-21, 96]. 
 
LDL-Cholesterol and related lipid targets 
Because of lack of clinical trial evidence [96, 97], clear therapeutic targets for 
plasma LDL-cholesterol cannot be categorically defined for FH [6-11, 13]. The 
following is synthesized from various international guidelines [6-13, 22, 59]. In 
heterozygous FH [6, 9], therapy should initially aim for at least a 50% 
reduction in plasma LDL-cholesterol, followed by an LDL-cholesterol of < 2.5 
mmol/L (absence of CHD or other major risk factors) and < 1.8 mmol/L 
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(presence of CHD or other major risk factors) [10-12]; three targets for LDL-
cholesterol according to CV risk stratification have also been described and 
are reasonable [8], but not universally ratified [97]. Untreated LDL-cholesterol 
burden, or life years exposure, should be considered a major risk factor for 
driving more intensive and/or earlier therapy [53]. However, all recommended 
targets are difficult to achieve in the majority of FH patients with currently 
available treatments [5, 8, 18], so that the maximal LDL-cholesterol reduction 
that can be tolerated with therapy is a pragmatic strategy, particularly for 
higher risk patients with FH. The LDL-cholesterol of homozygotes should 
accordingly be reduced as much as possible [8, 32, 64], noting subsequent 
recommendations on use of apheresis. Therapeutic targets for apoB and non-
HDL-cholesterol have not been defined in FH [8], but with co-existent 
metabolic syndrome or diabetes targets recommended by other expert bodies 
should be adopted [12-14, 59, 98]. A therapeutic target for Lp(a) has been 
specified elsewhere, but the evidence for its use in FH is limited [49]. Other 
than when investigating symptomatic patients or managing homozygotes [8], 
we do not consider that there is a role for cardiovascular imaging in monitoring 
and guiding therapy. 
 
Modification of lifestyle and non-cholesterol risk factors 
All patients with FH should be counselled on lifestyle modifications [6-14, 99]. 
Dietary modification to lower the intake of saturated fat, trans-unsaturated fat, 
and cholesterol contributes to improvements in the plasma lipid profile [100-
102]. A heart-healthy diet should be promoted and regular intake of fruits and 
vegetables, whole grains, tree nuts, low-fat and non-fat dairy products, beans, 
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fish and lean meats encouraged. Alcohol intake should be moderated and 
psychological stress addressed [8, 46]. Expert counselling may be indicated 
[102]. A Mediterranean-type diet supplemented with extra virgin olive oil or 
nuts may have particular benefits in FH [103], but its acceptance will be 
culturally dependent. Dietary supplementation with plant sterols or stanols 
may be employed to incrementally lower plasma LDL-cholesterol [104]. 
Avoidance and cessation of smoking is mandatory. Smoking cessation can be 
facilitated with either nicotine replacement products or drugs that modulate the 
intensity of nicotine withdrawal [11]. Passive smoking should also be 
discouraged in families. Hypertension should be treated to guideline levels 
[105]. Patients who are obese and/or insulin resistant should be counselled on 
weight loss and aerobic exercise regimens [8, 100-102]. Prior to initiation of 
an exercise regimen, some patients will warrant stress testing (electro- or 
echocardiography, nuclear perfusion scanning) to assess myocardial 
functional capacity and the possibility of silent ischaemia [11, 45, 106]. 
Diabetes should be treated according to recommended guidelines [107]. Low 
dose aspirin should be used in high risk FH and considered in lower risk 
patients [8, 11, 96]. 
 
Pharmacologic Therapy 
The mainstay of managing FH is therapy with a high potency statin, generally 
administered at the highest dose tolerated within 6 months of first consultation 
[6-9, 13]. Statins reduce the risk for cardiovascular events [108-113] and 
progression of atherosclerosis in FH [56], and their use is cost-effective [77, 
114, 115]. Adjuvant therapy with ezetimibe, bile acid sequestrants, plant 
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stanols/sterols, and niacin (or its derivatives) may often also be required [21, 
116-120]. Patients may require 3 or more drugs to achieve adequate LDL-
cholesterol reduction, which is particularly important in secondary prevention 
[8, 18, 120]. With hypertriglyceridaemia, use of fenofibrate or omega-3 fish oils 
may be advisable [13, 98], and niacin could be considered when plasma LDL-
cholesterol and/or Lp(a) are also not at target [49, 119]. Probucol is used in 
Japan, Korea and China. Probucol is a potent antioxidant and, despite 
lowering HDL-cholesterol, can regress xanthomata and reduce CVD events in 
FH [121]. 
 
The effectiveness of statins, ezetimibe and bile acid sequestrants relates to 
upregulation of hepatic LDLRs [41]. Given that patients with homozygous FH 
have a severe or total deficiency in LDLR function, their response to LDL 
lowering therapies is usually markedly attenuated [32]. Statins and ezetimibe 
can lower LDL-cholesterol in homozygous FH by potentially decreasing 
hepatic secretion of apoB [32, 122], but these patients usually require 
apheresis [32, 64]. Homozygous patients with LDLR null mutations (function 
<2% of normal) are less responsive to pharmacotherapy and have a worse 
prognosis than those with LDLR defective mutations (function 2-25% of 
normal) [32]. If apheresis is not available, consideration should be given to the 
addition of lomitapide [123] or mipomersen [124] to further lower LDL-
cholesterol, noting country-specific licensing and use of special access 
schemes. Although apparently safe in studies that have facilitated their 
approval for prescription use, experience with these new agents in clinical 
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practice is very early and careful attention to guidance from the manufacturers 
and the regulatory agencies is essential. 
It is critical to ensure that all FH patients adhere to the recommended 
treatment regimens [8, 125, 126]. Patients should be counselled on all 
aspects of their care, including the warning signs of drug related toxicity [125, 
126].  
 
Potential Medication Toxicity 
All systemically absorbed cholesterol-lowering therapies can potentially be 
hepatotoxic and myotoxic [118, 119], although in practice the chances of 
severe toxicity are extremely low. Given that the majority of patients with FH 
will be treated with two or more medications [8, 13, 18, 117], the risk for 
adverse events is higher than with monotherapy. Plasma hepatic 
aminotransferases should be measured prior to initiating a statin [127]. If 
baseline levels are abnormal, hepatic ultrasonography should be considered. 
A significant percentage of patients requiring drugs in developed and 
developing countries have insulin resistance and hepatic steatosis. Plasma 
glucose should particularly be monitored in all patients with impaired fasting 
glucose [128], as well as in those with risk factors for type 2 diabetes, 
including metabolic syndrome. Plasma aminotransferases should be 
monitored with statins [8, 127], noting the recent FDA recommendation that 
this need only be undertaken as clinically necessary and not routinely 
(http://fda.org/Drugs/DrugSafety/ucm293101.htm). Lipid lowering drugs should 
be discontinued if plasma aminotransferases increase to 3 times the upper 
limit of normal on two occasions within a period of one month. The specific 
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regimen can be re-evaluated and patients rechallenged with a different statin 
and then drugs re-introduced piecemeal with careful monitoring of plasma 
aminotransferases. Both mipomersen and lomitapide have FDA black box 
warnings concerning the potential risk of hepatotoxicity. 
 
Statin related myalgia is a significant problem in the community setting; it is 
dose-dependent and varies among statins [129, 130]. Patients should be 
counselled about warning signs of myopathy and rhabdomyolysis. Older age, 
frailty, reduced overall skeletal muscle mass, chronic kidney disease, 
hypothyroidism, alcoholism, underlying muscle disorders, and drug 
interactions all increase the risk of myopathy [130, 131]. Plasma creatine 
kinase (CK) levels and a careful physical examination should be performed 
prior to starting therapy, since there are many causes of myopathy and 
arthropathy other than statins [130, 131]. Similarly, patients reporting 
musculoskeletal symptoms on statins require careful clinical evaluation, 
including repeat plasma CK and exceptionally electromyography and referral 
to a specialist [130, 131]. The combination of gemfibrozil with a statin should 
be particularly avoided [129-131], the risk of myopathy being significantly 
lower with fenofibrate [132, 133]. Statin myopathy should be managed 
according to expert recommendations [59, 130, 131, 134]. Ezetimibe is well 
tolerated and has a statin dose-sparing effect [116, 117]. Bile acid 
sequestrants cause constipation and abdominal discomfort and can impair the 
absorption of anionic drugs and vitamins; tolerability is greatest with 
colesevelam [118, 135]. In addition to induction of flushing, patients treated 
with niacin should also be monitored for possible elevations in serum uric acid 
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and glucose and reductions in platelets [136]. Niacin combined with 
laropiprant, an anti-flushing agent, is no longer commercially available, owing 
to unfavourable outcomes in a recent trial [137]. Patients should report any 
new medications prescribed by other health care providers to minimize risk for 
drug interactions [118, 133]. Patients with reduced glomerular filtration rates 
may require dose adjustment of lipid modifying medications (e.g. specific 
statins or fibrates) [118]. Neither atorvastatin, pravastatin nor pitavastatin 
require dose adjustments with chronic kidney disease since they are not 
substantially renally excreted [118, 127]. 
 
Women: contraception, pregnancy and menopausal hormone therapy. 
Low estrogen-containing oral agents, intra-uterine devices and barrier 
techniques are the preferred methods of contraception for women with FH [8, 
22, 138, 139]. The latter two are preferable for those older than 35 years [8]. 
All women and girls of childbearing age should receive advice on 
contraception and pre-pregnancy counselling before starting a statin and this 
should be reviewed annually [8, 138, 140]. Statins and other systemically 
absorbed lipid regulating drugs should be discontinued 3 months prior to 
conception and during pregnancy and lactation [8, 138]. However, women 
who become pregnant accidentally while on a statin could be re-assured that 
the likelihood of foetal complications is low [8, 140]. 
 
Controlling hypercholesterolaemia during pregnancy is particularly important 
in women with established CHD [8, 9, 22]; it may also decrease the severity of 
FH in offspring who inherit the condition [141]. Bile acid sequestrants are the 
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only safe agents to control hypercholesterolaemia in pregnancy [8, 9, 118, 
142], but only modestly lower plasma LDL-cholesterol levels and 
gastrointestinal side-effects remain a problem [118, 135]; colesevelam is more 
tolerable than older resins. During breastfeeding, resins could be employed to 
lower LDL-cholesterol where indicated [8, 22]. More data are required on the 
outcomes of pregnancy in women with FH and on the effect of statins on the 
foetus in the first trimester [140]; an appropriate registry of patients is 
recommended [8]. Pregnant women with heterozygous FH and established 
CHD, or with homozygous FH, should be considered for apheresis [8, 9, 22, 
64, 142]. 
 
When one or both members of a couple have FH, several options may enable 
the couple to avoid having a child affected by FH. These include not 
conceiving, adoption, using donor gametes, prenatal diagnosis using chorionic 
villus sampling or amniocentesis, and pre-implantation genetic diagnosis [8]. 
Referral for expert counselling is accordingly recommended [8]. 
 
The effect of menopausal hormone therapy (MHT) on risk of CHD in 
postmenopausal women with FH is unclear. On the basis of data from other 
populations, MHT should be avoided in women with FH, except for relief of 
menopausal symptoms that cannot be controlled with safe natural remedies 
[22, 143, 144], in which case a regimen based on cyclical transdermal 
oestrogen should be employed. 
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Management of Children and Adolescents 
 
It is generally agreed that targets for LDL-cholesterol treatment in children 
need not be as low as adults [8, 9, 19, 20, 22, 65]. As in adults, good evidence 
for an absolute or relative target does not exist in children; international 
guidelines are consequently not uniform in their recommendations [8, 9, 19, 
20, 22, 65]. Early cholesterol-lowering treatment can substantially alter the 
natural history of FH [53, 56, 108-112, 145]. Although systematic reviews 
confirm the safety of currently employed statins in children [146, 147], the 
long-term sequelae of high intensity statin regimens are unknown. Good long-
term data on the safety of statins started early in life are therefore required 
[148, 149], emphasizing the need to establish a suitable international registry 
[150]. The plasma LDL-cholesterol targets for children aged 8 to 10 years 
should be < 4.0 mmol/L and for those older than 10 years < 3.5 mmol/L [8, 19, 
20, 22, 65, 66, 73, 145, 148]. Boys and girls should be treated to similar 
targets, but treatment targets could be lowered and therapy intensified in 
those with a particularly adverse family history of CHD or in the presence of 
other major cardiovascular risk factors [8, 19, 43, 44, 63, 65, 73]. Therapeutic 
targets for non-HDL-cholesterol, apoB and Lp(a) have not been clearly 
defined for children with FH. 
 
Treatment begins with a heart-healthy diet management that is best 
administered by a paediatric dietician [73, 101]. The diet should typically 
contain < 30% of calories from total fat, < 7% of calories from saturated fat, 
and ideally < 200 mg of cholesterol/day [20, 73, 101]. The diet should include 
nutrient dense foods with appropriate energy to maintain optimal body weight. 
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Fruits and vegetables, whole grains, low-fat dairy products, beans, fish and 
lean meats should be encouraged. Encouraging a Mediterranean diet may be 
beneficial and particularly acceptable in certain cultures [103]. Dietary 
supplementation with plant sterols or stanols (sitosterol or sitostanol) may be 
considered to lower LDL-cholesterol levels [151]. Physical activity should be 
promoted and active and passive smoking strongly discouraged [8, 20, 65, 66, 
73, 101]. Primordial prevention of the development of risk factors is advised 
[8, 20, 65, 66]. Additional existing cardiovascular risk factors should be treated 
according to recommended guidelines [73, 101]. FH is not only a disorder that 
should be diagnosed in a family context, but also managed in a similar 
manner; the entire nuclear family should be strongly encouraged to adopt and 
support adherence to a lifestyle that addresses all major cardiovascular risk 
factors. 
 
Drug treatment will be required in a great majority of patients with 
heterozygous FH and should be initiated in those with plasma LDL-cholesterol 
levels (measured on two occasions) above targets after diet management [8, 
19, 20, 22, 65, 73]. Agents tested in clinical trials and approved for use by 
regulatory agencies should be used [8, 19, 20, 22, 65, 66, 73]; statin drugs are 
preferred and should be initiated at low doses [146, 147]. Statin treatment with 
approved medications can be initiated at 8-10 years of age and not delayed 
until 18 years [8, 19, 20, 22, 65, 66, 73]. Children with a particularly adverse 
family history of CHD and other major risk factors could be considered for 
earlier treatment with statins [8, 19, 43, 44, 65, 73, 145]; this may be 
especially important in boys [1, 3, 43, 44]. If goals are not achieved, 
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consideration should be given to the addition of ezetimibe or bile acid 
sequestrants [8, 19, 65, 66, 148, 149]. Balancing the need to achieve LDL-
cholesterol targets with possible side effects should be considered in 
individualizing drug therapy [148, 149]. Children with homozygous FH should 
be referred to a specialist centre: medications should be initiated at diagnosis, 
higher potency statins in combination with other agents will be required, and 
apheresis must be considered [8, 19, 20, 22, 61, 65, 73, 152]. 
Prior to initiating statin therapy, plasma aminotransferases, CK, glucose, and 
creatinine should be measured [8, 19, 20, 22, 65, 148, 149]. After starting 
therapy, weight, growth, physical and sexual development should be 
monitored. Plasma aminotransferases should be monitored routinely, as 
should glucose and glycated haemoglobin if there are co-existent risk factors 
for diabetes. Plasma CK should be assessed if musculoskeletal symptoms are 
reported. Statin myopathy should be managed according to adult guidelines 
[129-131]. Adolescent girls should be counselled to stop statins when 
contemplating or at risk of pregnancy [8, 138, 140]. 
 
Paediatric patients with uncomplicated and well-controlled FH could be 
managed in general practice [8, 20, 65]. Patients with severely elevated LDL-
cholesterol, multiple cardiovascular risk factors, complications of 
pharmacologic therapy, or homozygous FH should be managed by a 
specialist [8, 20, 22, 65, 73]. Family and transitional care clinics are 
recommended [8, 65]. Carotid ultrasonography has been employed in 
research studies [52, 147], but its use and that of other cardiovascular 
imaging modalities cannot at present be recommended for monitoring therapy 
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in individual paediatric patients with heterozygous FH. Establishing clinical 
registries is essential for improving the overall care of paediatric patients with 
FH [150]. 
 
Lipoprotein apheresis and other invasive therapies 
 
Lipoprotein apheresis (LA) is an extracorporeal treatment that removes apoB-
containing lipoproteins from the circulation [64, 152, 153]. The removal of LDL 
by LA improves CHD outcomes, progression of atherosclerosis and aortic 
fibrosis, endothelial function and coagulation in FH [142, 153, 154]. LA is FDA 
approved therapy that is indicated for patients with homozygous (or 
compound heterozygous) FH or severe heterozygous FH with progressive 
CHD, who are refractory or intolerant to maximal pharmacotherapy [8, 22, 
142, 153-155]. By contrast to homozygous FH, the social/patient acceptability 
and cost-effectiveness of LA for treating refractory heterozygous FH remains 
unclear and needs further evaluation [156]. Elevation in plasma Lp(a) levels is 
a reimbursable indication for LA in Germany, but the evidence supporting the 
value of apheresis beyond reduction in LDL-cholesterol is questionable [152, 
154, 157]. In homozygous children, LA should be considered by age 5 years 
and no later than 8 years [8, 22, 152, 158]. Untreated patients with a 
homozygous phenotype typically have plasma LDL-cholesterol >13 mmol/L 
and should be treated with maximally tolerated pharmacotherapy for at least 6 
months before considering LA [8, 22, 64, 152-155]. Untreated heterozygotes 
typically have plasma LDL- cholesterol from 5 to 13 mmol/L and may be truly 
non-responders to or be intolerant of pharmacotherapy [8, 22, 32, 64]. LDL-
cholesterol criteria for selecting the above patients for apheresis have been 
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recommended elsewhere [8, 64, 152, 153, 155], but should be modified 
according to clinical context; simple criteria are a reduction in LDL-cholesterol 
of less than 50% or LDL-cholesterol > 5 mmol/L on diet and maximally 
tolerated pharmacotherapy, which should be continued during LA [8, 64]. 
Different thresholds for LDL-cholesterol may be set according to the 
availability of resources for apheresis. Patients must be psychologically and 
clinically stable and committed to treatment [8]. Imaging should be carried out 
at baseline to assess aortic stenosis and aneurysms [8, 22, 64, 152, 155]. 
Contraindications to apheresis methods employing heparin include 
haemorrhagic diatheses, resistance to adequate coagulation and 
hypersensitivity to heparin. LA is efficacious, tolerable and safe for children 
with severe FH and may be commenced after the age of 5 years [8, 152, 158, 
159], or earlier in exceptional circumstances. While lower body weight is a 
recognised risk factor for complications, successful outcomes have been 
reported with LA in very young children with homozygous FH [152, 159, 160]. 
Women with severe FH may be successfully treated during pregnancy [8, 22, 
155]. 
 
There are several LA methods that are selective for LDL and all acutely lower 
plasma LDL-cholesterol and Lp(a) levels by 50 to 70% following a single 
treatment [153, 155]. The FDA approved methods involve the extracorporeal 
precipitation of apoB-containing lipoprotein with dextran sulphate or heparin 
[142], while in other countries, alternative systems (immunoadsorption, double 
cascade filtration or haemoperfusion with direct absorption of lipoproteins 
units, dextran sulphate or polyacrylate) are available [64, 152, 153, 155]. 
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Plasma exchange may be used, but is not selective for LDL. The choice of 
method will depend on local expertise and resources [153, 155]. A major 
barrier is the cost of treatment, which is comparable to haemodialysis [8]. 
Therapeutic outcomes and costs can be optimized by collaborating with a 
specialty experienced in apheresis, such as transfusion medicine [8, 155]. The 
cost-effectiveness of treating homozygous FH with LA appears to be greater 
than for heterozygous FH, questioning whether present healthcare systems 
could meet a rising demand for LA posed by refractory heterozygous FH 
patients [156]. In developing countries, creative approaches, such as 
corporate support and public donations, should be adopted to support the 
funding of LA. There is a need for an extended international network of 
treatment centres and registry of patients on LA [150, 152, 157]. 
 
The frequency of LA should be adjusted to achieve a time-average plasma 
LDL-cholesterol concentration between therapy of < 6.5 mmol/L and < 2.5 
mmol/L for homozygotes and heterozygotes [8, 64, 155], respectively; a mean 
reduction of 65% in LDL-cholesterol relative to no treatment is a simple target. 
This will usually require an acute reduction of >70% in LDL-cholesterol and 
weekly or fortnightly treatments; weekly treatments may be required in very 
severe homozygous FH [152-155]. Statins should be continued to slow post-
exchange rebound in LDL-cholesterol [8, 64, 155]. Angiotensin converting 
enzyme inhibitors are contra-indicated with most systems, particularly the 
dextran sulphate LDL absorption and haemoperfusion methods, because of 
bradykinin reactions [8, 64, 152, 153]; side effects (nausea, hypotension, 
vasovagal episodes, hypocalcaemia, anaemia, sepsis) are not uncommon, 
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but are rarely serious. Patients who are intolerant of a particular method of LA 
should be tested on an alternative method, including plasma exchange if 
required [8, 64, 153]. Because of the demands of treatment, psychological 
status and quality of life should be addressed [8], recent data suggesting that 
lower quality of life may relate specifically to the severity of CVD [161]. Long-
term efficacy of treatment on carotid and aortic valve/root atherosclerosis 
should be assessed every 2 years in homozygotes using standard imaging 
methods [8, 155, 162]. Regular monitoring with exercise electro- or 
echocardiography and review by a cardiologist are recommended. 
 
Lomitapide should be considered as an adjunctive treatment to further lower 
LDL-cholesterol in adults with homozygous FH on LA [123, 152, 154], as well 
as in children and adolescents with homozygous FH (under special access or 
compassionate use schemes) on LA with rapidly progressive atherosclerosis. 
By contrast to lomitapide, experience with use of mipomersen has not yet 
been reported in homozygous FH patients on LA. In those who cannot tolerate 
lomitapide, mipomersen should be accordingly considered [124, 152, 154]. 
Novel LDL-cholesterol lowering therapies may reduce the need for or the 
frequency of LA in severe FH [152, 154, 163-165], but this needs to be 
demonstrated. 
Orthotopic liver transplantation should also be considered in younger 
homozygous patients when LA is not available, or cannot be tolerated, and 
LDL-cholesterol cannot be adequately controlled with intensive 
pharmacotherapy [8, 166]; pre-emptive transplantation has been proposed but 
experience is limited [167]. Coronary artery bypass surgery, aortic valve 
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replacement or a combined heart transplant should be considered according 
to clinical context prior to liver transplantation [168, 169]. Partial ileal bypass 
should be considered in heterozygous patients who are drug-intolerant [170]. 
Portacaval shunting can theoretically decrease the hepatic secretion of LDL in 
homozygous FH, but LDL-cholesterol reduction is variable and the procedure 
carries a high risk of encephalopathy; it could exceptionally be considered to 
treat severe homozygotes in countries where the above treatments are not 
available [171]. There may be a future role for gene therapy in treating severe 
FH [172, 173]. 
 
Emerging Therapies 
 
Many patients with FH cannot attain optimal and sustained reductions in 
plasma levels of LDL-cholesterol [18, 32]. This has prompted the development 
of highly innovative therapies that can provide substantive reductions in LDL-
cholesterol additional to standard therapies [164, 165], with significant 
implications also for the treatment of homozygous FH [174]. The long-term 
efficacy, safety and tolerability of these agents remain to be demonstrated, 
however. Clinical registries of patients treated with all new therapies is 
recommended [150]. 
 
PCSK9 Inhibition 
Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a serine protease 
secreted by hepatocytes that regulates the expression of the LDLR [175]. 
PCSK9 complexes with the LDLR and is taken up together with the adaptor 
protein ARH (autosomal recessive hypercholesterolemia) in clathrin coated 
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pits by hepatocytes [175]. PCSK9 either prevents the recycling of LDLR to the 
hepatocyte cell surface from the endosomal compartment or chaperones the 
LDLR to the lysosome for degradation [175]. Loss-of-function genetic variants 
in PCSK9 enhance hepatic LDL receptor activity, with significant lifelong 
reductions in plasma LDL-cholesterol and reduced risk of CHD [175]; 
conversely, dominant gain-of-function mutations lead to a phenotype similar to 
FH [2, 175].  
 
Therapeutic human monoclonal antibodies (Mabs) against PCSK9 increase 
both the residence time of LDLR on the cell surface and receptor density, 
leading to augmented clearance of LDL-cholesterol from the circulation [175]. 
REGN727/SAR236553 demonstrates a dose-response capacity to reduce 
serum levels of LDL-cholesterol (40-72%) in patients with heterozygous FH 
receiving statin therapy with or without ezetimibe [176] and in patients with 
primary hypercholesterolaemia with or without statin therapy [177, 178]. 
Similarly, AMG 145 demonstrates a dose-response capacity to reduce plasma 
LDL-cholesterol 41-66% and has been tested in patients with heterozygous 
FH [179], as well as in primary hypercholesterolaemia with or without statin 
therapy [180, 181]. AMG 145 can also lower plasma LDL-cholesterol in 
receptor defective homozygous FH patients [182]. Importantly, PCSK9 Mabs 
also significantly reduce plasma apoB, total cholesterol, non-HDL-cholesterol, 
and Lp(a) [175-181]. These Mabs are in phase 3 trials and are not yet 
approved for use, but clearly hold great promise either as monotherapy or 
adjuvant therapy in the management of FH [164, 165, 175]. The long-term 
efficacy and safety of these agents needs to be established In FH. 
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Mipomersen 
Mipomersen (Kynamro™) is an antisense 20-mer oligonucleotide that binds to 
a complementary sequence messenger RNA encoding apoB, thereby 
inhibiting ribosomal translation [183]. By inhibiting the biosynthesis of apoB, 
hepatic VLDL production and secretion are significantly reduced. Mipomersen 
consists of a phosphorotioate backbone and 2’-O-(2-methoxyethyl)-modified 
ends which provide biological stability [183]. Subsequent to subcutaneous 
injection, Mipomersen is concentrated in the liver where it undergoes 
catabolism via the action of hepatic endonucleases and exonucleases [183]. 
Mipomersen is FDA approved for use in patients with homozygous FH. 
Mipomersen has been shown to reduce serum LDL-cholesterol by 
approximately 25%, 28%, and 36% in patients with homozygous FH [124], 
heterozygous FH [184], and severe hypercholesterolemia with or without CHD 
[185], respectively. Mipomersen also induces substantial reductions in total 
cholesterol, apoB, triglycerides, non-HDL-cholesterol, and Lp(a) [124, 183-
185]. In addition to frequent injection site reactions and short-lived fatigue and 
myalgia, mipomersen can induce hepatic steatosis (assessed by magnetic 
resonance imaging) in 16% of patients, as well as elevations in plasma 
aminotransferases in 8% of patients [124, 183-185]. These hepatic changes 
apparently resolve on discontinuing the drug [183]. Mipomersen has orphan 
drug status and, because of the risk of hepatotoxicity, in the US can only be 
prescribed through a Risk Evaluation Mitigation Strategy (REMS) program 
(http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPa
tientsandProviders/ucm111350.htm). 
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Lomitapide 
Microsomal triglyceride transfer protein (MTP) localizes to the endoplasmic 
reticulum of hepatocytes and enterocytes and transfers triglycerides into VLDL 
in the liver and chylomicrons in the intestine [186]. Lomitapide (Juxtapid™) is 
an oral MTP inhibitor that decreases the hepatic production and secretion of 
VLDL. Lomitapide is licensed for the treatment of homozygous FH in the US 
and Europe as an add-on therapy [186]. In a multi-centre study of such 
patients lomitapide reduced LDL-cholesterol by 50%, 44%, and 38% at 26, 56, 
and 78 weeks respectively [123]. Lomitapide therapy may also result in 
significant reductions in other lipids and lipoproteins, including total 
cholesterol, apoB, triglyceride, non-HDL-cholesterol, and Lp(a) [123, 186]. 
Lomitapide may be hepatotoxic, can elevate plasma aminotransferases, and 
can increase intrahepatic fat content by approximately 6% after 26 and 78 
weeks of therapy [123, 186]. Cytochrome P450 3A4 inhibitors increase 
exposure to lomitapide [186]. It can induce gastrointestinal symptoms related 
to reduced small intestine absorption of fat, so that dietary fat restriction is 
frequently required to control such symptoms. Lomitapide may reduce the 
absorption of fat-soluble vitamins and essential fatty acids, so co-
administration of appropriate supplements is recommended. Because of the 
risk of hepatotoxicity, in the US lomitapide must also be prescribed through an 
FDA approved REMS program. 
 
Mipomersen and lomitapide are both FDA approved for homozygous FH. 
PCSK9 inhibitors are not yet licensed for use in FH, but clinical trial data 
suggest that they may have broad applications for patients with heterozygous 
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FH, who are not at LDL-cholesterol targets on maximal statin therapy [164, 
165, 176, 179] or who are intolerant to statins [187]. All three classes of 
agents may reduce the need for LA and other radical therapies for severe FH. 
The results of trials of cholesteryl ester transfer protein inhibitors have been 
universally disappointing to date [164, 165], but the efficacy of anacetrapib is 
currently being tested in a large study of patients with heterozygous FH [164]. 
 
Organization and Development of Care 
 
In spite of the recent explosion of interest and research in FH, the care of 
patients and families remains suboptimal [18, 21, 25, 188-190]. This provides 
an important mandate to standardise and improve service delivery at all 
levels. The development and implementation of initiatives and strategies to 
improve the care of FH requires a close collaboration between healthcare 
systems, patient support groups and related non-government organizations 
and health networks [8, 31, 33, 97, 191, 192]. Care pathways for patient flow 
among all health providers, including primary care, should be developed and 
be specified for local needs [8, 31, 33, 97]. Establishing a national network of 
clinics managing people with FH is recommended for standardising care and 
facilitating research [8, 80, 189, 190]. FH urgently needs an International 
Classification of Diseases (ICD)-10 and/or a Diagnosis-Related Groups (DRG) 
code to standardise assessment of quality outcomes and organisational 
performance, as well as to facilitate research, healthcare financing and re-
imbursement strategies. 
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Models of care for FH should be multidisciplinary [8, 31, 33] and, in principle, 
centrally co-ordinated [5, 8, 31, 33, 80, 193]. Services should be managed by 
personnel accredited in cardiovascular prevention [8, 31, 194], and should 
address all aspects of care, including health-related quality of life [46, 195]. 
Well controlled and low complexity patients could be transitioned to primary 
care for long-term management, while high complexity patients should be 
followed-up by a service with special expertise in lipid management [8, 31, 
33]. Review intervals will vary according to clinical context. Patients with 
severe FH on apheresis require careful lifetime follow-up by specialist 
services [8, 64, 152, 155]. Primary care providers have an important role in 
detecting index cases [8, 27], but cascade screening should be co-ordinated 
centrally within a framework that integrates specialist and primary care [8, 27, 
31, 193]. Education and training of primary care providers in lipid 
management is important for improving and maintaining the total quality of 
care [8, 33, 196]. A structured review should be offered at least annually to all 
patients [8, 33]. This is particularly important for low complexity patients who 
may be more at risk of loss to follow-up; the process could be centrally 
monitored via a registry [150]. A telehealth programme should be employed 
for remote care [8, 197]. Children are best reviewed in a specialist paediatric 
clinic, with appropriate arrangement made for transitional care [8, 18, 20, 65]; 
an adult-paediatric clinic may be useful for families [65].  
 
Nurses have a role in co-ordinating screening, as well as in clinical care, 
medication support, education and training, audit and research, 
multidisciplinary liaison [8, 80, 198-200] and working with a family support 
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group [8, 31, 33]. Dietetic services are highly desirable [8, 99-101]. Advice 
from health and adolescent psychologists [46, 82, 201] and exercise 
physiologists [102] may be required. Pharmacists may have a special role in 
case detection, medication support and research [8, 202]. A multidisciplinary 
approach should be adopted to address the quality of life of FH patients on 
various treatment modalities. 
 
Links with clinical genetics are important for special counselling during 
cascade screening [8, 201]. Not all families or patients with FH require genetic 
counselling, but some exposure and basic training in the principles of genetic 
counselling is important for managing FH [8, 78, 201]. 
 
FH services should also have close links with laboratory medicine and access 
to routine and advanced lipid analyses [8, 30, 31]. DNA testing should only be 
carried out by accredited laboratories that can screen for mutations in all the 
major genes of interest [8, 78, 86]. Adequate patient assessment requires 
access to cardiac and imaging facilities, including treadmill testing, myocardial 
perfusion scanning and ultrasonography; close links with cardiology are 
essential [7, 8, 54, 203]. Collaboration with a transfusion medicine or dialysis 
unit is important for managing apheresis [8, 152, 153, 155]. 
 
A specialised database for storing clinical and family data and information 
technology support systems is essential for effective provision of services [8, 
30, 31]. Computerised programs should be capable of pedigree drawing, 
workflow management, production of template letters, archiving data, clinical 
audits and research. An international database with information on mutations 
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recognised as causing FH [95] is available, but should be developed for those 
countries or healthcare systems adopting DNA testing [84-86]. 
 
A well-designed and comprehensive clinical registry provides invaluable 
information for research and audit, as well for improving the quality of care 
[26, 150]. A registry can facilitate the co-ordination of cascade screening at a 
local, community and national level, increasing also the cost-efficiency of DNA 
testing where a mutation has been previously identified and registered in a 
family [150]. Hybrid enrolment options, including patient enrolment, may 
enhance the identification of FH. Every effort should be made to establish an 
active association for patients and families via a support group [8, 30, 31]. 
This forum can provide a useful network for facilitating mutual support and 
education, establishing an effective advocacy group and interacting with 
health policy makers, and developing a national registry of affected families. 
All models of care must address the perspectives and requirements of 
patients and families [46, 195]. 
 
Conclusion: into the future 
 
This international guidance is derived from knowledge of best contemporary 
practice, and aims to achieve the best outcomes for patients with FH by 
providing a standard of practice that will hopefully remove variability and 
inequalities in the care of FH worldwide. The recommendations cannot, 
however, meet universal needs for the care of FH. They therefore need to be 
complemented by judicious clinical judgment and adjusted for country-specific 
and local healthcare needs and resources. Clinical trials in people with FH are 
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needed to close evidence gaps. Research agendas should be broad, but also 
specific to national and local needs. Research should ideally be conducted by 
clinical networks and integrated into a quality cycle to improve the 
development of models of care [204]. FH requires an ICD-10 classification 
code as a matter of priority. Future developments in the healthcare of FH 
need to evolve within the framework of the Chronic Care Model [23], and 
hence in a positive policy environment. This will entail establishing effective 
partnerships with a wide spectrum of stakeholders, including patient support 
groups, public participants, heart foundations and related non-government 
organizations, universities and academic centres, as well as with health 
economists, policy makers and government ministers [8, 191, 192].
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RA (Advisor), JD (Chairman), JJPK (Hon. President)), ML (Executive 
Director), PM (Trustee), RDS (Advisor), GFW (Trustee). The International FH 
Foundation, a UK based Not For Profit Charity, was commissioned with the 
major aim of improving the care of FH worldwide. An international board of 
patients, clinicians and other skilled representatives has set new targets to 
address strategic priorities, which through continually improving 
communications between clinicians with interests in FH, aims to establish and 
support new country foundations, campaigning, consensus, research, 
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Process: 
GFW and DS arranged a series of workshops and discussions at the 
International Atherosclerosis Society (Sydney 2012) that involved 16 
members of the group and addressed evidence for treatment, screening and 
DNA testing, paediatric management, novel therapies, health economics, 
regional diversity in management, and models of care. Workshop moderators 
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(GFW, DS, SG, AW, PPT) identified and collated consensus-based on 
published research, clinical experience, common themes, expert opinion and 
other international guidelines on FH. To gauge wider international opinion a 
brief questionnaire on potentially contentious issues in FH (screening options, 
DNA testing, risk stratification, testing and treatment of children, use of 
imaging, and therapeutic targets) was completed by all members of the group 
and a group of 26 international experts. The majority view was employed to 
inform further consensus, as discussed and agreed by group members (AW, 
JD, ML, PPT, BT, RDS, WGS, GFW) at a satellite workshops arranged by the 
International FH Foundation at the 80th Congress of the European 
Atherosclerosis Society (Milan, 2012) and the World Congress of Clinical 
Lipidology (Budapest, 2012). GFW produced a first copy of the 
recommendations and manuscript, which was subsequently extended and 
revised by SG, AW and PPT, with additional comments received from all 
members of group. At three teleconferences GFW, SG, AW and PPT 
discussed and fully concurred on the levels of evidence and gradings for the 
recommendations, based on previous consensus, published literature and 
expert opinion. The recommendations were again discussed and agreed with 
selected group members (AW, PM, FJR, BT, RA, ML) at a workshop at the 
81st Congress of the European Atherosclerosis Society (Lyon, 2013), also 
arranged by the International FH Foundation. The writing committee re-
examined a pre-final draft of the paper and again reached full consensus on 
the recommendations of the guidance. GFW then prepared a final draft of the 
paper. All members approved the final document before submission. The 
recommendations and documents were also reviewed and fully endorsed by 
the National Lipid Association in August 2013.
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WGS, DRS, AVS, BT, SY, JK); Mochida Pharma (SY); Novartis (GFW, EB, 
KKL, KGP, AVS, BT, JK); Omthera Pharma (AVS, JK); Ono Pharma (SY); 
Otsuka (SY); Pfizer (WVB, KKL, KGP, FJR, RDS, EJGS, DRS, AVS, SY, JK); 
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Pronova Biopharma Norge A.S. (JK); Ranbaxy (BT); Randox (WGS); 
Regeneron Pharma (ML, JD, JK); Resverlogix (JK); Roche (GFW, EB, KGP, 
WGS, DRS, BT); Sanofi (GFW, RA, WVB, EB, KKL, ML, PM, KGP, FJR, 
RDS, DRS, AVS, JK); Servier (BT); Siemens (WGS); Shionogi (SY); Sticares 
Cardiovascular Research Foundation (JK); Synexus Ltd (JK); Takeda (BT, 
SY); Teijin (SY); Vascular Research Network (JD); The Medicines Company 
(JK); UniQure Inc (JK); Vascular BioGenics Ltd (JK); Xenon Pharma (JK).
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Appendix: FH and related websites  
 
 British Heart Foundation 
www.bhf.org.uk 
Leading British foundation provides excellent resources for health professionals 
and patients, including informative videos on a wide spectrum of conditions and 
risk factors. 
 
 FH Australasia Network, Australian Atherosclerosis Society  
www.athero.org.au/FH  
Website of the FH Australasia Network providing educational material and 
support for patients and health professionals caring for FH. An integrated model 
of care for GPs that facilitates screening, diagnosis and referral pathways is 
included. The FH Network is currently working to create a unique web-based FH 
Registry that could be linked internationally. 
 
 FHChol Austria, Austrian FH Patient Organisation 
www.fhchol.at 
Austrian patient support organization that provides support information and 
education for patients and families on all aspects of the detection and 
management of FH. 
 
 FH Guideline Implementation Team Toolkit 
www.heartuk.org.uk/FHToolkit  
Invaluable resource for implementing the seminal NICE guideline 71 on 
identification and management of FH. 
 
 FH Norway, Norwegian FH Patient Organisation 
www.f-h.no 
Norwegian patient support organization that provides support information and 
education for patients and families on all aspects of the detection and 
management of FH. 
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 FH Support Group of Western Australia 
www.fhfamilysupportgroup.websyte.com.au 
Website of the first support group in Australia for families with FH; provides 
relevant information, communication and support services. 
 
 FH Portugal, Portugese FH Patient Organisation 
www.fhportugal.pt 
Portugese patient support organization that provides support information and 
education for patients and families on all aspects of the detection and 
management of FH. 
 
 Foundation for the Identification of Persons with Inherited 
Hypercholesterolaemia (StoEH) 
www.stoeh.nl 
Premier organization for case detection in The Netherlands that promotes 
essential information for patients with FH; to be reviewed in association with 
general information on CVD (www.hartenvaatgroup.nl); www.jojogenetics 
provides full guidance on DNA Testing for healthcare providers. 
 
 German FH Patient Organization 
www.cholco.org 
German organization that provides support information and education for patients 
and families with FH, as well as for health professionals and policy makers. 
 
 HEART UK 
www.heartuk.org.uk 
Leading UK cholesterol charity that provides extensive resources for health 
professionals, patients and families on all aspects of the detection and 
management of FH. 
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 Hipercol Brasil 
www.hipercolesterolemia.com.br 
Website for FH patients and health professionals maintained by the Heart 
Institute (InCor), University of Sao Paulo Medical School Hospital; provides 
information about FH in the Portuguese language concerning how to screen and 
make a clinical and genetic diagnosis of FH in Brazil.  
 
 Human Genetics Society of Australasia 
www.hgsa.org.au  
Premier Australasian society that provides educational materials, training, 
polices, guidelines and position statements on all aspects of human genetics. 
 
 International FH Foundation 
www.fh-foundation.org  
Foundation, formed from the merger of MEDPED-International and HEART-EU, 
that has a vision of a world in which FH is routinely screened for and treated. 
Provides key support for patients, families, researchers and health professionals. 
 
 Japan Atherosclerosis Society 
www.j-athero.org 
Information in Japanese on FH for both patients and general practitioners; to be 
reviewed in association with website for the patient association 
www.apheresis.web.fe2.com. 
 
 Learn Your Lipids, NLA 
www.learnyourlipids.com  
Information for patients with dyslipidaemia, including FH, as provided by the 
foundation of the National Lipid Association in the US. 
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 Lipids Online, Baylor College of Medicine 
www.lipidsonline.org  
Established on-line facility, coordinated by Baylor College of Medicine (Houston, 
Texas, US), providing resources (slides, visual meetings, commentaries), for 
clinicians, researches and educators on several aspects of dyslipidaemia, 
atherosclerosis and cardiovascular disease. 
 
 Make Early Diagnosis Prevent Early Death (MEDPED) FH 
www.medped.org 
US based website of the original MEDPED Project coordinated by the University 
of Utah School of Medicine (Salt Lake City, Utah, US) focusing on all aspects of 
the management of FH, including education of patients and families and the first 
attempt at establishing a US registry. 
 
 National Genome Research Institute, National Institutes of Health 
www.genome.gov/25520184  
General information on FH. 
www.genome.gov/11510372 
Clinical useful tools for evaluating family history. 
www.genome.gov/11510371 
Informative resources on general genetics for all health professionals. 
 
 National Heart Foundation, Australia 
www.heartfoundation.org.au 
Leading Australian charity that provides a wealth of resources for health 
professionals and the community on all aspects of primary and secondary 
prevention of cardiovascular disease. 
 
 National Lipid Association (NLA), US 
www.lipid.org 
US based multidisciplinary specialty society providing education, training, 
guidelines and position statements on all aspects of the detection and 
management of dyslipidaemia and related disorders. 
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 New Zealand Guidelines Group 
www.nzgg.org.nz  
New Zealand group of experts that specialises in developing and implementing 
guidelines for best clinical practice; excellent resources on the assessment and 
management of all cardiovascular risk factors.  
 
 The FH Foundation 
www.thefhfoundation.org 
Patient centred foundation in US dedicated to raising awareness of FH through 
education, advocacy and research; currently working to establish the first 
comprehensive national FH Registry, with a launch in 2013. 
 
 Spanish FH Foundation 
www.colesterolfamiliar.org 
An exemplary foundation providing support and education for patients and 
families with FH, as well as for health professionals and policy makers; also 
includes a national registry for research and audit purposes.  
 
 Preventive Cardiovascular Nurses Association (PCNA) 
www.pcna.net/patients/familial-hypercholesterolemia 
The US based PCNA provides information on meetings, online education, 
advocacy and news on cardiovascular risk prevention relevant to FH. A useful 
patient tearsheet on essentials of FH suitable for people in different countries is 
available. 
 
 Public Health Genomics Foundation, UK 
www.phgfoundation.org 
International foundation that publishes authoritative reports on the role of 
advances in genomics in health care; has a particularly excellent document on 
services for inherited cardiovascular conditions. 
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 Wales FH Testing Service, Cardiff University 
www.fhwales.co.uk 
Leading FH service in the UK that provides useful information and resources for 
clinical practice, including activities of FH Family Forum.  
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